MCM
CPRX

MAI Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

MAI Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,326
Closed -$132K – 2612
2026
Q1 		$132K Buy
5,326
+5,208
+4,414% +$124K ﹤0.01% 1698
2025
Q4 		$2.75K Hold
118
– – ﹤0.01% 3334
2025
Q3 		$2.33K Sell
118
-219
-65% -$4.5K ﹤0.01% 3272
2025
Q2 		$7.31K Buy
+337
New +$7.96K ﹤0.01% 2882

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's CPRX Position: Q2 2026 in Review

MAI Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 5,326 shares — an estimated $132K sold.

MAI Capital Management first reported a position in CPRX in Q2 2025 and held it in 4 quarters. The position peaked at $132K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • MAI Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 5,326 Catalyst Pharmaceutical shares in Q2 2026, an estimated $132K.
  • MAI Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2025 and held it in 4 quarters.
  • MAI Capital Management's Catalyst Pharmaceutical position peaked at $132K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.